Literature DB >> 34014543

Metabolism of Immune Cells in the Tumor Microenvironment.

Jin G Jung1, Anne Le2,3.   

Abstract

The tumor microenvironment (TME) is a complex biological structure surrounding tumor cells and includes blood vessels, immune cells, fibroblasts, adipocytes, and extracellular matrix (ECM) [1, 2]. These heterogeneous surrounding structures provide nutrients, metabolites, and signaling molecules to provide a cancer-friendly environment. The metabolic interplay between immune cells and cancer cells in the TME is a key feature not only for understanding tumor biology but also for discovering cancer cells' vulnerability. As cancer immunotherapy to treat cancer patients and the use of metabolomics technologies become more and more common [3], the importance of the interplay between cancer cells and immune cells in the TME is emerging with respect to not only cell-to-cell interactions but also metabolic pathways. This interaction between immune cells and cancer cells is a complex and dynamic process in which immune cells act as a determinant factor of cancer cells' fate and vice versa. In this chapter, we provide an overview of the metabolic interplay between immune cells and cancer cells and discuss the therapeutic opportunities as a result of this interplay in order to define targets for cancer treatment. It is important to understand and identify therapeutic targets that interrupt this cancerpromoting relationship between cancer cells and the surrounding immune cells, allowing for maximum efficacy of immune checkpoint inhibitors as well as other genetic and cellular therapies.

Entities:  

Keywords:  CAR T lymphocytes; Immunometabolism; Metabolic barrier; Metabolic competition; Tumor immunity

Mesh:

Year:  2021        PMID: 34014543     DOI: 10.1007/978-3-030-65768-0_13

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  108 in total

1.  Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division.

Authors:  Geon Kook Lee; Hyeon Jin Park; Megan Macleod; Phillip Chandler; David H Munn; Andrew L Mellor
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

Review 2.  Gene-engineered T cells for cancer therapy.

Authors:  Michael H Kershaw; Jennifer A Westwood; Phillip K Darcy
Journal:  Nat Rev Cancer       Date:  2013-08       Impact factor: 60.716

Review 3.  Improving T cell therapy for cancer.

Authors:  Ann M Leen; Cliona M Rooney; Aaron E Foster
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

4.  Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Jeffrey R Lee; Kanchan G Jhaver; Theodore S Johnson; Derin B Keskin; Brendan Marshall; Phillip Chandler; Scott J Antonia; Russell Burgess; Craig L Slingluff; Andrew L Mellor
Journal:  Science       Date:  2002-09-13       Impact factor: 47.728

5.  Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.

Authors:  Paulo C Rodriguez; David G Quiceno; Jovanny Zabaleta; Blair Ortiz; Arnold H Zea; Maria B Piazuelo; Alberto Delgado; Pelayo Correa; Jason Brayer; Eduardo M Sotomayor; Scott Antonia; Juan B Ochoa; Augusto C Ochoa
Journal:  Cancer Res       Date:  2004-08-15       Impact factor: 12.701

6.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

Review 7.  Big opportunities for small molecules in immuno-oncology.

Authors:  Jerry L Adams; James Smothers; Roopa Srinivasan; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2015-07-31       Impact factor: 84.694

Review 8.  Adoptive T cell therapy for cancer in the clinic.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-06       Impact factor: 14.808

9.  Application of metabolomics technologies toward cancer prognosis and therapy.

Authors:  Giang Hoang; Sunag Udupa; Anne Le
Journal:  Int Rev Cell Mol Biol       Date:  2019-08-07       Impact factor: 6.420

10.  Immunoregulatory Interplay Between Arginine and Tryptophan Metabolism in Health and Disease.

Authors:  Giada Mondanelli; Alberta Iacono; Massimo Allegrucci; Paolo Puccetti; Ursula Grohmann
Journal:  Front Immunol       Date:  2019-07-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.